derivatives of Treprostinil, prodrugs of Treprostinil, polymorphs of Treprostinil or isomers of Treprostinil.

10. A composition according to any one of claims 7 to 9, wherein the bone marrow disease is leukaemia, a defect of the blood cell compartment, bone marrow diseases induced by chemotherapy or irradiation.

11. A composition according to claim 10, wherein said defect of the blood cell compartment is haemoglobinopathy or a defect in neutrophil granulocyte function.

12. A composition according to any one of claims 7 to 11, for use in the treatment of subjects suffering from bone marrow disease by administering a prostacyclin analogue for at least 7 days, preferably for at least 10 days, preferably for at least 14 days after bone marrow transplantation.

13. A composition comprising at least one prostacyclin analogue and stimulated haematopoetic stem cells.

14. A composition according to any one of claims 7 to 13 which is a pharmaceutical composition.

15. A composition according to any one of claims 7 to 14 further comprising forskolin.

16. A composition according to any one of claims 7 to 15 for intravenous or subcutaneous administration, or orally available form selected from the group of sustained release forms, tablets and capsules.

17. A method according to any one of claims 1 to 6 or a composition according to any one of claims 7 to 16, wherein said stem cells are derived from cord blood, donor bone marrow or placenta.

18. Use of a composition comprising at least one prostacyclin analogue in the manufacture of a medicament for the treatment of bone marrow disease.

19. The use according to claim 18, wherein said prostacyclin analogue is selected from the group of Treprostinil, Iloprost, Cicaprost and Beraprost or pharmaceutically acceptable salts thereof.

20. The use according to claims 18 or 19, wherein said prostacyclin analogue is Treprostinil preferably a derivative of Treprostinil selected from the group of acid derivatives of Treprostinil, prodrugs of Treprostinil, polymorphs of Treprostinil or isomers of Treprostinil.

21. The use according to any one of claims 19 to 20, wherein the bone marrow disease is leukaemia, a defect of the blood cell compartment, bone marrow diseases induced by chemotherapy or irradiation.

22. The use according to claim 21, wherein said defect of the blood cell compartment is haemoglobinopathy or a defect in neutrophil granulocyte function.

23. The use according to any one of claims 19 to 22, wherein the prostacyclin analogue is to be administered for at least 7 days, preferably for at least 10 days, preferably for at least 14 days after bone marrow transplantation.

24. The use according to any one of claims 18 to 23, wherein the composition is a pharmaceutical composition.

25. The use according to any one of claims 18 to 24, wherein the composition further comprises forskolin.

26. The use according to any one of claims 18 to 25, wherein the composition is for intravenous or subcutaneous administration, or in an orally available form selected from the group of sustained release forms, tablets and capsules.

27. The use according to any one of claims 18 to 26, wherein the composition comprises at least one prostacyclin analogue and stimulated haematopoetic stem cells.

28. The use according to claim 27, wherein said stem cells are derived from cord blood, donor bone marrow or placenta.